Clinical Genetics Branch,Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland, USA.
Cancer Prev Res (Phila). 2011 Mar;4(3):303-6. doi: 10.1158/1940-6207.CAPR-11-0053.
In this issue of the journal, Cramer and colleagues and Zhu and colleagues report carefully designed phase 3 assessments of candidate ovarian cancer screening biomarkers. The main conclusion is that CA-125 remains the "best of a bad lot"; the new candidates have fallen short of expectations. We review factors impeding the development of an effective ovarian cancer screening strategy, highlight the requirements related to validating proposed screening biomarkers, and emphasize the risks from premature clinical applications of unvalidated tests, all underscoring the need for new research strategies.
在本期杂志中，Cramer 及其同事以及 Zhu 及其同事报告了精心设计的候选卵巢癌筛查生物标志物的 3 期评估。主要结论是 CA-125 仍然是“差中之差”；新的候选者未能达到预期。我们回顾了阻碍有效卵巢癌筛查策略发展的因素，强调了与验证拟议筛查生物标志物相关的要求，并强调了未经验证的测试过早临床应用的风险，所有这些都强调了需要新的研究策略。
